Currently, diagnosis of autism spectrum disorders (ASD) is based on psychological and behavioral evaluations.
These tests:
  • can not be performed on infants and very young children
  • require social and language skills
  • require child cooperation
  • are time-consuming and prohibitively expensive.
Yet early signs of ASD are often apparent at the infant stage of development, including lack of eye movement, smiles and response to the environment. If at this stage, a simple blood test was available to objectively diagnose ASD, then early biological intervention would be possible and more likely to be successful due to brain plasticity of the developing child. This would lead to earlier intervention with behavioral therapies.


Cell-El is working to identify blood-borne, ASD-specific diagnostic markers. Our preliminary analyses of a broad panel of bio-markers have identified markers discriminating between typically developed (TD) children and children with ASD.  Based on these findings, a diagnostic tool and a promising targeted biological treatment are being developed. Cell-El’s innovative diagnostic research is developing a targeted curative approach for ASD.

Read more about our scientific method and published research: